Mind Medicine (NASDAQ: MNMD) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% ...

周二，专注于迷幻药研究的生物科技公司Mind ...

Inc. (NASDAQ:MNMD – Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $7.32, but opened at $7.15. Mind Medicine (MindMed) shares last traded ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Robert Barrow, the Chief Executive Officer of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), a $502 million market cap company that has delivered an impressive 108% return... Mark Sullivan ...

Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase I for Pain.

Mind Medicine (MNMD) announced that it will be ... and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) shares were down 8.5% on Friday following insider selling activity. The company traded as low as $6.98 and last traded at $6.98.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Chardan initiated coverage of Mind Medicine (MNMD) with a Buy rating and $20 price target The firm cites the potential of the company’s lead asset MM120 for the treatment of generalized anxiety ...

Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel ...